Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling
Pharmaceutics · 06.05.2023 · 15 (5) · 1424
DOI: 10.3390/pharmaceutics15051424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.05.2023. Verfasst von Tom G Jacobs und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, Bill and Melinda Gates Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic kidney disease (CKD) are absent or not supported by clinical data. Physiologically based pharmacokinetic (PBPK) models have the potential to facilitate dose selection for these drugs in this population. Existing lamivudine and emtricitabine compound models in Simcyp® (v21) were verified in adult populations with and without CKD and in non-CKD paediatric populations. We developed paediatric CKD population models reflecting subjects with a reduced glomerular filtration and tubular secretion, based on extrapolation from adult CKD population models. These models were verified using ganciclovir as a surrogate compound. Then, lamivudine and emtricitabine dosing strategies were simulated in virtual paediatric CKD populations. The compound and paediatric CKD population models were verified successfully (prediction error within 0.5- to 2-fold). The mean AUC ratios in children (GFR-adjusted dose in CKD population/standard dose in population with normal kidney function) were 1.15 and 1.23 for lamivudine, and 1.20 and 1.30 for emtricitabine, with grade-3- and -4-stage CKD, respectively. With the developed paediatric CKD population PBPK models, GFR-adjusted lamivudine and emtricitabine dosages in children with CKD resulted in adequate drug exposure, supporting paediatric GFR-adjusted dosing. Clinical studies are needed to confirm these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Department of Pharmacology and Toxicology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Department of Pediatrics, Erasmus MC-Sophia's Children's Hospital, 3015 CN Rotterdam, The Netherlands.
ORCID-Profile: Tom G Jacobs
Förderung
- Bill & Melinda Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Jacobs, T. G., de Hoop-Sommen, M. A., Nieuwenstein, T., van der Heijden, J. E. M., de Wildt, S. N., Burger, D. M., Colbers, A., & Freriksen, J. J. M. (2023). Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling. Pharmaceutics, 15(5), 1424. https://doi.org/10.3390/pharmaceutics15051424
Vancouver
Jacobs TG, de Hoop-Sommen MA, Nieuwenstein T, van der Heijden JEM, de Wildt SN, Burger DM, et al. Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling. Pharmaceutics. 2023;15(5):1424. doi:10.3390/pharmaceutics15051424
BibTeX
@article{Jacobs2023,
author = {Jacobs, Tom G and de Hoop-Sommen, Marika A and Nieuwenstein, Thomas and van der Heijden, Joyce E M and de Wildt, Saskia N and Burger, David M and Colbers, Angela and Freriksen, Jolien J M},
title = {Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1424},
doi = {10.3390/pharmaceutics15051424}
}
EUVIMED